ReviewDrugs & aging2010
Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
Review in Drugs & aging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 8 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2023Pooled it
- Effects of herpes zoster vaccination and antiviral treatment on the risk of stroke: a systematic review and meta-analysis.Frontiers in neurology · 2023Pooled it
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2019Pooled it
- Vaccines for preventing herpes zoster in older adults.The Cochrane database of systematic reviews · 2016Pooled it
- Evaluation of the economic burden of Herpes Zoster (HZ) infection.Human vaccines & immunotherapeutics · 2015Pooled it
- Vaccines for post-exposure prophylaxis against varicella (chickenpox) in children and adults.The Cochrane database of systematic reviews · 2014Pooled it
- Is herpes zoster vaccination likely to be cost-effective in Canada?Canadian journal of public health = Revue canadienne de sante publique · 2014Pooled it
- A systematic review of the cost effectiveness of herpes zoster vaccination.PharmacoEconomics · 2013Pooled it
- Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.Human vaccines & immunotherapeutics · 2013Trial
- Immunogenicity and safety of ZOSTAVAX(®) approaching expiry potency in individuals aged ≥50 years.Human vaccines · 2011Trial
- Development of mRNA vaccines against herpes zoster.Human vaccines & immunotherapeutics · 2026Review
- Herpes Virus Infection in Lung Transplantation: Diagnosis, Treatment and Prevention Strategies.Viruses · 2023Review
- Ocular Inflammation Post-Vaccination.Vaccines · 2023Review
- Comparing Prodrugs with Acyclovir for Treating Postherpetic Neuralgia among Herpes Zoster Patients: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2022Review
- A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two decades including those in clinical trials for the current novel SARS-CoV-2.RSC advances · 2021Review
- Recombinant zoster vaccine (ShingrixThe Korean journal of pain · 2020Review
- Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.BMC infectious diseases · 2017Review
- Prevention of Herpes Zoster and its complications: From clinical evidence to real life experience.Human vaccines & immunotherapeutics · 2017Review
- Herpes zoster and the search for an effective vaccine.Clinical and experimental immunology · 2017Review
- Herpesvirus Respiratory Infections in Immunocompromised Patients: Epidemiology, Management, and Outcomes.Seminars in respiratory and critical care medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individuals who have been infected with varicella zoster virus (VZV) are at risk for developing herpes zoster and this risk appears to be related to a decline in VZV-specific cell-mediated immunity (CMI). Zostavax (zoster vaccine) is a one-dose, high-potency, live, attenuated VZV vaccine that boosts VZV-specific CMI and this is its presumed mechanism of action. Zoster vaccine is registered in the EU for use in adults aged >or=50 years for the prevention of herpes zoster and herpes zoster-related postherpetic neuralgia. In the Shingles Prevention Study, a placebo-controlled trial in adults aged >or=60 years (n = 38 546), zoster vaccine led to a sustained boost of VZV-specific CMI. Over a mean herpes zoster surveillance period of 3.1 years, zoster vaccine reduced the herpes zoster-related burden of illness by 61%, reduced the incidence of herpes zoster by 51% and reduced the incidence of postherpetic neuralgia by 67%. Zoster vaccine recipients who developed herpes zoster had a shorter illness duration and severity than placebo recipients who developed herpes zoster. Zoster vaccine had continuing efficacy in a Shingles Prevention Study subpopulation followed for 7 years post-vaccination. Zoster vaccine was generally well tolerated in older adults. While cost-effectiveness estimates in pharmacoeconomic analyses varied widely according to vaccine and herpes zoster parameter cost/benefit estimates, an analysis from a UK perspective found a zoster vaccine immunization programme in adults aged 65 years to be cost effective. In older adults, the zoster vaccine has the potential to significantly reduce the herpes zoster burden of illness by decreasing the incidence of herpes zoster or reducing its severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.